European Institute of Oncology

Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study

Background Evidence regarding outcomes in patients with hormone receptor (HR)-positive/HER2-negative breast cancer (BC) with a second consecutive ipsilateral locoregional recurrence (LRR) remains limited. Methods Single-center, cohort study including consecutive patients with HR-...

Mapping the NFYA 3′UTR landscape identifies alternative polyadenylation as a targetable vulnerability in prostate cancer

Abstract Background Alternative polyadenylation (APA) is increasingly recognized as a pervasive oncogenic mechanism that reshapes post-transcriptional gene regulation and promotes tumor aggressiveness. Whether APA contributes to the dysregulation of NFYA —encoding the regulatory...

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

PURPOSE: Treatment options for progression on first-line endocrine therapy (ET)+CDK4/6i for ER-positive/HER2-negative (ER+/HER2-) advanced breast cancer (ABC) include ET plus targeted agents (CDK4/6i or PI3K/AKT/mTOR-pathway inhibitors). Elacestrant is the first single-agent oral...

Benchmarking generative AI tools for literature retrieval and summarization in genomic variant interpretation

Abstract Background Generative AI is increasingly used to extract structured information across domains, but its reliability in academic and clinical research, where precision and accuracy are essential, remains largely unexplored. This study evaluates the ability of Large Langua...

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Summary Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real‐world observational data outside randomized clinical trials remain limited...

Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer

OBJECTIVE: Incidental prostate cancer (PCa) patients are currently stratified to either cT1a vs. cT1b stage, depending on tumor volume (< 5% vs. > 5%) in the resected tissue. We tested for other models that could improve cancer-specific survival (CSS) predictions. METHODS: Incide...